



## Advair Diskus<sup>®</sup> (fluticasone propionate/salmeterol) – First-time generic

- On January 30, 2019, the [FDA announced](#) the approval of [Mylan's Wixela<sup>™</sup> Inhub<sup>™</sup>](#), a generic version of GlaxoSmithKline's [Advair Diskus \(fluticasone propionate/ salmeterol\)](#) inhalation powder.
  - Mylan expects to launch Wixela Inhub in the second half of February.
- Advair Diskus is approved for the twice-daily treatment of asthma in patients aged 4 years and older, and for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
- Fluticasone propionate/salmeterol is also available generically as [inhalation powder](#) and brand inhalation aerosol ([Advair HFA<sup>®</sup>](#)).
  - The inhalation powder and Advair HFA are approved for the treatment of asthma in patients aged 12 years and older.
- According to IQVIA data, Advair Diskus had sales of \$4.2 billion for the 12 months ending November 30, 2018.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.